MRKMerck Sharp & Dohme LLCFinished
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Carcinoma, Nonsquamous Non-small-cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,003 (final count)
- Started
- Jun 28, 2019
- Main results expected
- Feb 7, 2024
- Fully finished
- Jan 30, 2026
- Results posted
- Feb 6, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: Up to ~31 months
Overall Survival (OS)
Measured over: Up to ~51 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03976323 · record last updated 2026-09-28 · checked 2026-11-09 15:47 UTC